ArticleTranslational lung cancer research2026
Cisplatin re-challenge following recovery from carboplatin-induced, biopsy-proven acute tubular necrosis in a 57-year-old patient with squamous-transformed non-small cell lung cancer: a case report.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cisplatin-based chemotherapy remains a key treatment option for advanced non-small cell lung cancer (NSCLC), particularly in patients with squamous histology or those who develop histologic transformation after resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Squamous transformation represents an uncommon but clinically challenging resistance mechanism, often associated with limited therapeutic options and continued reliance on platinum-based regimens. However, prior platinum-associated acute tubular necrosis (ATN), particularly when histologically confirmed, frequently precludes further use of platinum in clinical practice. This creates a critical therapeutic dilemma in which effective treatment options are limited; however, re-administration of platinum agents is considered high-risk. Evidence regarding the safety of cisplatin re-challenge after recovery from biopsy-proven ATN is extremely limited, leaving clinicians without clear guidance. Case Description: We describe the case of a 57-year-old Japanese man who developed squamous transformation after osimertinib treatment and subsequently experienced carboplatin-induced biopsy-proven ATN following the first cycle of chemoimmunotherapy. Serum creatinine increased from 0.76 to 1.55 mg/dL, with a decline in estimated glomerular filtration rate (eGFR) from 83.82 to 37.83 mL/min/1.73 m Conclusions: This case suggests that cisplatin re-challenge should be considered in carefully selected patients after recovery from biopsy-proven platinum-associated ATN, when clinically necessary. Importantly, our findings highlight that even in the setting of recurrent AKI, treatment continuation may be feasible under strict multidisciplinary management, including intensive hydration, electrolyte correction, and close nephrology involvement. Rather than demonstrating general safety, this case provides a clinically relevant framework for risk assessment and management in situations where therapeutic options are limited. However, these observations were derived from a single case and should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.